1. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemi- ology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012; 4: 19–37. https://doi.org/10.2147/ HMER.S16316 PMID: 24367230
2. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infec- tion and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158: 329–337. https://doi.org/10.7326/0003-4819-158-5-201303050-00005 PMID:23460056
3. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19: 223–238. https://doi.org/10.1016/j.cld. 2015.01.001 PMID: 25921660
4. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014; 74: 2377–2384. https://doi.org/10.1158/0008-5472.CAN-13-2971 PMID: 24717177
5. Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004; 292: 2130– 2140. https://doi.org/10.1001/jama.292.17.2130 PMID: 15523074
6. Kamb A. What’s wrong with our cancer models? Nat Rev Drug Discov. 2005; 4: 161–165. https://doi. org/10.1038/nrd1635 PMID: 15688078
7. DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 2013; 94: 329–335. https://doi.org/10.1038/clpt.2013.117 PMID:23739536
8. European Association for the Study of The Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908–943. https://doi.org/10.1016/j.jhep.2011.12.001 PMID: 22424438
9. Bruix J, Sherman M. American Association for the Study of Liver Diseases, Management of hepatocel- lular carcinoma: an update. Hepatology. 2011; 53: 1020–1022. https://doi.org/10.1002/hep.24199PMID: 21374666
10. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK path- way, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851–11858. https://doi.org/10.1158/0008-5472.CAN-06-1377PMID: 17178882
11. Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011; 11: 524–534. https://doi.org/ 10.4161/cbt.11.5.14677 PMID: 21258214
12. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603–607. https://doi.org/10.1038/nature11003 PMID: 22460905
13. Alexander JJ, Bey EM, Geddes EW, Lecatsas G. Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J. 1976; 50: 2124–2128. PMID: 63998
14. entiated human liver carcinoma-derived cell line. Nature. 1979; 282: 615–616. https://doi.org/10.1038/282615a0 PMID: 233137
15. Huh N, Utakoji T. Production of HBs-antigen by two new human hepatoma cell lines and its enhance- ment by dexamethasone. Gan. 1981; 72: 178–179. PMID: 6268479
16. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gan. 1976; 67: 1–10. PMID: 57894
17. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982; 42: 3858–3863. PMID: 6286115
18. Fujise K, Nagamori S, Hasumura S, Homma S, Sujino H, Matsuura T, et al. Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Hepatogastroenterol- ogy. 1990; 37: 457–460. PMID: 1701409
19. Dor I, Namba M, Sato J. Establishment and some biological characteristics of human hepatoma cell lines. Gan. 1975; 66: 385–392. PMID: 52570
20. Hirohashi S, Shimosato Y, Kameya T, Koide T, Mukojima T, Taguchi Y, et al. Production of alpha-feto- protein and normal serum proteins by xenotransplanted human hepatomas in relation to their growth and morphology. Cancer Res. 1979; 39: 1819–1828. PMID: 85491
21. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer. 1995; 62: 276–282. https://doi.org/10.1002/ijc. 2910620308 PMID: 7543080
22. Lee JH, Ku JL, Park YJ, Lee KU, Kim WH, Park JG. Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA. World J Gastroenterol. 1999; 5: 289–295. https://doi.org/10.3748/wjg.v5.i4.289 PMID: 11819450
23. Homma S. Studies on the establishment and some biological characteristics of cultured human liver cancer cell lines. Their growth, functional and morphological characteristics and temperature sensitivi- ties. Jikeikai Med J. 1985; 32: 289–315.
24. Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE, et al. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res. 1987; 47: 6710–6718. PMID: 3479249
25. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977; 59: 221–226. https://doi.org/10.1093/jnci/59.1.221 PMID: 327080
26. Mabbott NA, Baillie JK, Brown H, Freeman TC, Hume DA. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics. 2013; 14: 632. https://doi.org/ 10.1186/1471-2164-14-632 PMID: 24053356
27. Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: still unmet expecta- tions. World J Hepatol. 2017; 9: 80–90. https://doi.org/10.4254/wjh.v9.i2.80 PMID: 28144389
28. Sawey ET, Chanrion M, Cai C, Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differWu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell. 2011; 19: 347–358. https://doi.org/10.1016/j.ccr.2011.01.040 PMID: 21397858
29. Wilhelm SM, Dumas J, Adnane L, et al. Lynch M, Carter CA, Schu¨ tz G, Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129: 245–255. https://doi.org/10.1002/ijc.25864 PMID: 21170960
30. Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014; 20: 2959–2970. https://doi.org/10.1158/1078-0432.CCR-13-2620 PMID: 24700742
31. Chen B, Sirota M, Fan-Minogue H, Hadley D, Butte AJ. Relating hepatocellular carcinoma tumor sam- ples and cell lines using gene expression data in translational research. BMC Med. Genomics. 2015; 8: S5. https://doi.org/10.1186/1755-8794-8-S2-S5 PMID: 26043652
32. Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, et al. Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response. Gastro- enterology. 2019; 157: 760–776. https://doi.org/10.1053/j.gastro.2019.05.001 PMID: 31063779
33. Qiu Z, Li H, Zhang Z, Zhu Z, He S, Wang X, et al. A pharmacogenomic landscape in human liver can- cers. Cancer Cell. 2019; 36: 179–193. https://doi.org/10.1016/j.ccell.2019.07.001 PMID: 31378681
34. Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepato- cellular carcinoma. J Hepatol. 2016; 65: 798–808. https://doi.org/10.1016/j.jhep.2016.05.007 PMID:27212245
35. Peng JM, Bera R, Chiou CY, Yu MC, Chen TC, Chen CW, et al. Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in mice. Hepatology.2018; 67: 2226–2243. https://doi.org/10.1002/hep.29678 PMID: 29171033
36. Wan S, Meyer AS, Weiler SME, Rupp C, To´th M, Sticht C, et al. Cytoplasmic localization of the cell polarity factor Scribble supports liver tumor formation and tumor cell invasiveness. Hepatology. 2018; 67: 1842–1856. https://doi.org/10.1002/hep.29669 PMID: 29152770
37. Hoshida Y, Nijman SMB, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69: 7385–7392. https://doi.org/10.1158/0008-5472.CAN-09-1089 PMID: 19723656
38. Mizutani A, Koinuma D, Tsutsumi S, Kamimura N, Morikawa M, Suzuki HI, et al. Cell type-specific target selection by combinatorial binding of Smad2/3 proteins and hepatocyte nuclear factor 4alpha in HepG2 cells. J Biol Chem. 2011; 286: 29848–29860. https://doi.org/10.1074/jbc.M110.217745 PMID:21646355
39. Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology. 2019; 156: 492–509. https://doi. org/10.1053/j.gastro.2018.11.001 PMID: 30404026
40. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carci- noma: paradigms for viral-related human carcinogenesis. Oncogene. 2006; 25: 3823–3833. https://doi. org/10.1038/sj.onc.1209559 PMID: 16799624
41. Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Tang GN, et al. Hepatitis B virus X protein (HBx)- related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology. 2013; 57: 1882–1892. https://doi.org/10.1002/hep.26195 PMID: 23239537
42. Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology. 1993; 18:781–789. https://doi.org/10.1002/hep.1840180406 PMID: 8406351